Organon & Co. (NYSE:OGN) Shares Bought by Deseret Mutual Benefit Administrators

Deseret Mutual Benefit Administrators boosted its position in shares of Organon & Co. (NYSE:OGN) by 24.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 6,256 shares of the company’s stock after buying an additional 1,222 shares during the quarter. Deseret Mutual Benefit Administrators’ holdings in Organon & Co. were worth $93,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Sippican Capital Advisors grew its position in Organon & Co. by 4.3% during the third quarter. Sippican Capital Advisors now owns 15,230 shares of the company’s stock valued at $291,000 after buying an additional 627 shares during the period. Commerce Bank grew its position in Organon & Co. by 5.5% during the third quarter. Commerce Bank now owns 12,168 shares of the company’s stock valued at $233,000 after buying an additional 637 shares during the period. MassMutual Private Wealth & Trust FSB grew its position in Organon & Co. by 32.4% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company’s stock valued at $41,000 after buying an additional 672 shares during the period. Graypoint LLC grew its position in Organon & Co. by 6.2% during the third quarter. Graypoint LLC now owns 14,555 shares of the company’s stock valued at $278,000 after buying an additional 853 shares during the period. Finally, CIBC Asset Management Inc grew its position in Organon & Co. by 4.9% during the fourth quarter. CIBC Asset Management Inc now owns 25,523 shares of the company’s stock valued at $381,000 after buying an additional 1,184 shares during the period. Institutional investors and hedge funds own 77.43% of the company’s stock.

Organon & Co. Stock Down 1.4 %

Shares of NYSE OGN opened at $15.47 on Friday. The company’s 50-day simple moving average is $15.36 and its 200-day simple moving average is $17.27. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. The firm has a market cap of $3.98 billion, a price-to-earnings ratio of 4.64, a price-to-earnings-growth ratio of 0.90 and a beta of 0.76. Organon & Co. has a 52-week low of $13.87 and a 52-week high of $23.10.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings results on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.09). The business had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.57 billion. Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. Equities analysts predict that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 13th. Stockholders of record on Monday, February 24th will be paid a $0.28 dividend. This represents a $1.12 annualized dividend and a dividend yield of 7.24%. The ex-dividend date of this dividend is Monday, February 24th. Organon & Co.’s dividend payout ratio is currently 33.63%.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Barclays dropped their price target on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. TD Cowen upgraded shares of Organon & Co. to a “hold” rating in a research report on Wednesday, January 15th. Finally, Morgan Stanley dropped their target price on shares of Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating on the stock in a research report on Friday, February 14th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, two have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $20.80.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.